Mavenclad may help manage coexisting autoimmune diseases alongside MS, potentially reducing the need for extra drugs.

Octave Bioscience, Inc., a commercial-stage precision neurology company pioneering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases such as Parkinson’s disease, ...

Sanofi said it received European Union approval for Cenrifki, a new multiple sclerosis medicine, after U.S. regulators rejected it.

Multiple sclerosis (MS) can have a substantial impact on many aspects of life beyond physical health, with 51% of people ...

One of the uncomfortable truths about multiple sclerosis is that the part of the brain likely to reveal the most about the disease and how a patient will be affected has been mostly invisible to ...

Although certain diets are sometimes touted as solutions for multiple sclerosis, they often lack evidence to support their ...

Researchers say ability to see for the first time previously hidden indicators of MS disease progression is an important advance.

Why does multiple sclerosis progress quickly in some people, while others remain stable for years? Researchers from the ...

An analysis of data from phase 3 randomized controlled trials showed that among individuals with comparable disease duration, inflammatory disease activity was significantly lower in older trial ...

Some research suggests that people with multiple sclerosis are at a higher risk of atherosclerosis. An increased risk hasn’t been established, and we don’t know how MS might increase the risk. Having ...

Multiple sclerosis is a disease that results when the immune system mistakenly attacks the brain and spinal cord. It affects nearly one million people in the U.S. and over 2.8 million worldwide. While ...